Lamal

Lamotrigine, the active ingredient in Lamal, is a sodium channel blocker presented as an oral tablet for oral use. It is prescribed for the treatment of epilepsy and as maintenance therapy in bipolar disorder, helping to control seizures and stabilize mood in adults and adolescents.

GNH USA supplies Lamal as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product conforms to EU regulatory standards and is manufactured under GMP conditions.

Lamotrigine is used in neurological and psychiatric conditions that involve abnormal neuronal excitability.

- Epilepsy (partial seizures, generalized tonic‑clonic seizures): reduces seizure frequency and severity. - Bipolar disorder (maintenance therapy): helps prevent recurrence of mood episodes and stabilizes mood. - Post‑operative seizure prophylaxis (brain tumor or neurosurgery): decreases the risk of postoperative seizures.

Lamotrigine may cause a range of adverse reactions, which are generally classified by frequency and severity.

Common Side Effects: - Dizziness - Headache - Nausea - Mild skin rash

Serious or Rare Side Effects: - Stevens‑Johnson syndrome or toxic epidermal necrolysis - Severe hypersensitivity reactions (e.g., DRESS syndrome) - Aseptic meningitis

When prescribing lamotrigine, clinicians should consider several safety measures to minimise risk.

- Initiate therapy at low dose: gradual titration reduces the risk of rash. - Monitor for skin reactions: discontinue immediately if a severe rash develops. - Assess hepatic or renal impairment: dose adjustment may be required. - Review concomitant medications: enzyme inducers or inhibitors can alter lamotrigine levels. - Store at ambient temperature: keep below 25 °C in the original pack, protect from moisture.

Lamotrigine’s plasma concentration can be affected by other medicines, necessitating careful review of co‑administered drugs.

Major Interactions (Avoid): - Valproic acid: markedly increases lamotrigine levels, raising toxicity risk. - Carbamazepine or phenytoin: significantly lower lamotrigine levels, reducing efficacy.

Moderate Interactions (Monitor Closely): - Oral contraceptives: may decrease lamotrigine concentrations, requiring dose adjustment. - Other enzyme inducers (e.g., phenobarbital, primidone): can reduce lamotrigine exposure. - Serotonergic agents (e.g., SSRIs): may increase the risk of rash.